Wedbush reaffirmed their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in a report released on Thursday,Benzinga reports. Wedbush currently has a $22.00 price target on the stock.
Separately, William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Wednesday, March 12th.
Get Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 7.8%
TLX stock traded down $1.37 during midday trading on Thursday, hitting $16.09. The stock had a trading volume of 33,163 shares, compared to its average volume of 26,093. Telix Pharmaceuticals Limited American Depositary Shares has a 52 week low of $13.61 and a 52 week high of $30.36. The stock has a 50-day simple moving average of $16.97 and a 200 day simple moving average of $16.92.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 26,939 shares of the company's stock, valued at approximately $451,000.
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
